• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Frequency Therapeutics prices $84m IPO

October 3, 2019 By Sean Whooley

Frequency Therapeutics updated logoFrequency Therapeutics said yesterday that it priced its initial public offering at roughly $84 million.

The 6-million-share offering priced at $14 per share and includes a 30-day underwriters option on another 900,000 shares that’s worth $12.6 million, the Woburn, Mass.-based company said.

Frequency said it expected to begin trading the shares on the NASDAQ exchange today under the “FREQ” ticker symbol. The offering is slated to close Oct. 7.

J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book-running managers for the offering.

Last month, Frequency registered the IPO at $100 million, saying it intended to use the funds to advance the clinical development of FX-322, the hearing loss drug it’s developing, as well as to develop other product candidates in its progenitor cell activation platform.

FX-322 is designed to stimulate the regrowth of sensory hair cells to treat chronic noise-induced hearing loss. Frequency’s technology is based on activating progenitor cells – mature stem cells that can proliferate into different types of cells. The compound is injected into the middle ear in a slow-release gel. Frequency did not disclose what the funds from its latest IPO might be earmarked for.

In July, the company raised $62 million in Series C funding that, combined with a $42 million Series B round in January and another $32 million from Series A funding in 2017, brought its total raise to $147 million.

Filed Under: Featured, Funding Roundup, Initial Public Offering (IPO), Otolaryngology Ear, Nose & Throat, Wall Street Beat Tagged With: Frequency Therapeutics

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS